Most patients with EGFR-mutated NSCLC respond very well to first-generation EGFR-TKIs (e.g., gefitinib and erlotinib) or second-generation EGFR-TKIs (e.g., afatinib and dacomitinib). Here, EGFR is linked to non-small cell lung carcinoma.